MEGHAN CONLIN/Herald photoApparently eight is not enough.The last time the UW women’s basketball team played against Penn State, head coach Lisa Stone only had eight available players, and her quote before the game was, “Eight is enough.”However, the Badgers were not able to rally around Stone’s saying and suffered a 69-54 defeat.This time around, however, it was the Lady Lions who only had eight available players as junior starter Charity Renfro did not travel with the team due to a concussion.Just like Wisconsin, Penn State was not able to achieve victory with a shorthanded roster, as the Badgers cruised to a 66-56 win behind a strong second half.The game was neck-and-neck through much of the first half, but a Rashida Mark put-back bucket at the buzzer gave Penn State a two-point lead at intermission. Following the play, Stone was clearly upset with her team’s mediocre play.”When we play the way we did in the first half — you know, spotty and just not finishing and kind of playing like there’s a snowstorm outside — you need to get upset a little bit,” Stone said. “And they answered and played very well in the second half.”Wisconsin began to break away in the second half behind the hot shooting of senior Ashley Josephson, as she was a perfect three-for-three from beyond the arc after half-time.”I tried to forget about what happened in the first half, and then it’s a new 20 minutes,” Josephson said. “So I had to go out there with a fresh mind and just stroke the ball.”While Josephson’s shooting in the second half helped propel Wisconsin to its first Big Ten home victory since New Year’s, Penn State head coach Rene Portland felt that it was Danielle Ward’s presence inside that made the difference.”The effectiveness of Ward (was the key),” Portland said. “They got the ball inside. She was able to stand and get position for a long time in there, and our kids didn’t handle that.”Ward’s improved play has been evident as of late, as she has gained more and more experience in just her sophomore year.The secret to her recent big games — most notably the Michigan State loss this past weekend, when she posted a 10-point, nine-rebound and six-block performance — is actually quite simple.”I just play,” Ward said. “There’s nothing about confidence or anything specific. Sometimes I just go into a zone and I’m just playing where I’m not worrying about anything — not worried about a turnover, not worried about a foul, not worried about the other team scoring or anything.”In Thursday night’s victory, Ward was all over the place with her physical style of play, scoring a game-high 16 points on 7-of-14 shooting with six rebounds and three blocks.She was simply too much for the Lady Lions.”I don’t think our kids handled the physical play, to be honest,” Portland said. “I obviously took a technical foul. … The frustration from that carried into how bad they played.”But it wasn’t just Ward or Josephson that made the difference; Wisconsin led a balanced scoring attack all around, with each starter scoring in double figures.With the win, Wisconsin started its three-game home stand to finish the season on a high note, and, with only two games and the Big Ten tournament remaining on the schedule, the question of what the team is capable of remains.”Anybody’s capable of anything,” Josephson said. “You see upsets all the time, so if we come out and play the basketball, anything can happen for us, so we just got to stay confident and keep playing the way we are and we’ll see what happens.”
A trust fund created by billionaire shipping tycoon Daniel K. Ludwig ends today with a bang and a gift to research. Six U.S. medical centers will receive $540 million—$90 million each—from the fund to endow cancer studies in perpetuity, or until cancer is no longer a problem, as specified in the will left by Ludwig, who died in 1992. In all, his estate has given $2.5 billion to cancer research since the 1970s.The new money goes to Ludwig Centers already located at six elite research institutions: Harvard Medical School in Boston; Johns Hopkins University in Baltimore, Maryland; the Massachusetts Institute of Technology in Cambridge; the Memorial Sloan-Kettering Cancer Center in New York City; Stanford University in Palo Alto; and the University of Chicago. The Ludwig trust had established the same centers in 2006.The funding by the Ludwig trust has been “sort of under the radar,” says oncologist Kenneth Kinzler, who, along with Bert Vogelstein, co-directs the Ludwig Center at Hopkins. These are among the most coveted awards in biomedicine, Kinzler says. The money is held as an endowment and comes with few strings attached—just a mandate to investigate cancer and find ways to stop it. There are no progress reports or renewal applications to write, Kinzler says, which “allows you to focus on what you think will yield the most important results without being concerned about meeting artificial intermediate deadlines.”Sign up for our daily newsletterGet more great content like this delivered right to you!Country *AfghanistanAland IslandsAlbaniaAlgeriaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic of theCook IslandsCosta RicaCote D’IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and Mcdonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People’s Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People’s Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMartiniqueMauritaniaMauritiusMayotteMexicoMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorwayOmanPakistanPalestinianPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalQatarReunionRomaniaRussian FederationRWANDASaint Barthélemy Saint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofVietnamVirgin Islands, BritishWallis and FutunaWestern SaharaYemenZambiaZimbabweI also wish to receive emails from AAAS/Science and Science advertisers, including information on products, services and special offers which may include but are not limited to news, careers information & upcoming events.Required fields are included by an asterisk(*)The Ludwig group seeks clinical outcomes, Kinzler says, a goal that he and Vogelstein strongly endorse. Without the Ludwig money, the Hopkins group would not have been able to do the cancer genetics studies they’re famous for, he notes—for example, the duo has used exome surveys to identify genes associated with colon and breast cancers.The sheer size of the Ludwig endowments makes a difference, says cancer immunologist Jedd Wolchok at Memorial Sloan-Kettering: “It allows for a respectable research budget.” Wolchok figures that his group’s budget for cancer immunology research will double this year, rising by “several million dollars,” and likely will continue to grow, thanks to the money earned by the endowment. For Wolchok, that means that “we can go from concept to clinical investigation very, very quickly.” For example, he expects his group to launch a clinical trial in 2 months to test a therapeutic antibody developed by a Japanese company that could be used to modulate T cells that regulate the immune response. The Memorial Sloan-Kettering team also has a series of clinical trials under way to monitor immune system reactions to various cancer therapies, including radiation.Ludwig, a friend of President Richard Nixon, was a stalwart backer of Nixon’s “War on Cancer,” which was linked to the congressional legislation that reestablished the U.S. National Cancer Institute in 1971. That year, the shipping magnate created an independent outfit in New York City, the Ludwig Institute for Cancer Research. The organization now has an endowment of more than $1.2 billion and employs more than 600 people, including scientists in six countries outside the United States, according to institute CEO Edward McDermott Jr.The philosophy that drives this research network, McDermott says, is the one that drove Ludwig “in his personal business enterprises—to find the best people and resource them well.” McDermott adds: “We invest in scientists, not particular science. … We are not in the business of discovery for discovery’s sake. It’s a means to an end, which is improved patient outcomes. So we are very committed to … infrastructures that allow us to take our discoveries from bench to bedside.” McDermott says that the institute has sponsored more than 100 clinical trials and has eight under way right now. All of these focus on cancer immunotherapy.
Your mom wasn’t joking about vitamin C. But you shouldn’t just drink it in OJ—you’re going to want to slather the stuff all over your face.Turns out, vitamin C (also known as ascorbic acid) has some crazy-amazing, research-backed benefits that can help you look younger, glowier, and altogether better. No torturous beauty treatments required. (We’re looking at you, Madonna, and your fork facial.)What is ascorbic acid?Ascorbic acid (a.k.a. vitamin C) is an antioxidant that provides lots of important nutritional benefits—like boosting your immune system and preventing heart disease and eye problems.But it has a LOT of beauty benefits, too. Ascorbic acid can combat sun damage, reduce inflammation, brighten pigmentation, and stimulate new and healthy collagen formation in skin (leading to fewer wrinkles and firmer skin). Translation: major glow-up.How is it different from other types of vitamin C?While there is a lot of research backing its benefits, formulating the vitamin so that it stays stable enough to produce visible results can be tricky. L-ascorbic acid, the pure form of ascorbic acid, is among the most potent and stable forms to look for in skin-care products.If you’re about to buy a product that says it has vitamin C, check the ingredients list to see if ascorbic acid or l-ascorbic acid is mentioned. If not, check for these other research-backed derivatives of vitamin C: retinyl ascorbate, ascorbyl palmitate, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, and ascorbyl glucoside. That way you’ll know you’re getting a truly effective product.How do you use ascorbic acid?Ascorbic acid is usually found in serums and moisturizers. Since all forms of vitamin C easily break down when exposed to air and sunlight, you should look for packaging like air-tight pumps that are dark or opaque, and store the products in a cool place out of the sun.Vitamin C is most effective when applied every night before bedtime, followed by dousing on a broad-spectrum sunscreen in the morning. Since it’s an antioxidant, vitamin C can work with your sunscreen to make your protection even stronger (although don’t use it on its own to protect you from the sun!)Source